| Base and prime editing technologies for blood disorders P Antoniou, A Miccio, M Brusson Frontiers in genome editing 3, 618406, 2021 | 50 | 2021 |
| Base-editing-mediated dissection of a γ-globin cis-regulatory element for the therapeutic reactivation of fetal hemoglobin expression P Antoniou, G Hardouin, P Martinucci, G Frati, T Felix, A Chalumeau, ... Nature Communications 13 (1), 6618, 2022 | 26 | 2022 |
| Adenine base editor–mediated correction of the common and severe IVS1-110 (G> A) β-thalassemia mutation G Hardouin, P Antoniou, P Martinucci, T Felix, S Manceau, L Joseph, ... Blood 141 (10), 1169-1179, 2023 | 20 | 2023 |
| Novel genome-editing-based approaches to treat motor neuron diseases: Promises and challenges A Miccio, P Antoniou, S Ciura, E Kabashi Molecular Therapy 30 (1), 47-53, 2022 | 16 | 2022 |
| Epigenetic regulation of β-globin genes and the potential to treat hemoglobinopathies through epigenome editing L Fontana, Z Alahouzou, A Miccio, P Antoniou Genes 14 (3), 577, 2023 | 4 | 2023 |
| Editing the LRF repressor binding site in the γ-globin promoters induces therapeutically relevant fetal hemoglobin levels for the treatment of β-hemoglobinopathies G Frati, P Antoniou, G Hardouin, B Mlaya, L Weber, T Felix, A Casini, ... Blood 136, 33, 2020 | 2 | 2020 |
| Improved nuclease-based prime editing by DNA repair modulation and pegRNA engineering P Antoniou, L Dacquay, N Selfjord, K Madeyski-Bengtson, AL Loyd, ... bioRxiv, 2024.02. 01.578377, 2024 | 1 | 2024 |
| Base Editing-Mediated Dissection of the-200 Region of the γ-Globin Promoters to Induce Fetal Hemoglobin and Rescue Sickle Cell Disease and β-Thalassemia P Antoniou, G Hardouin, P Martinucci, T Felix, L Fontana, J Martin, G Frati, ... Blood 138, 562, 2021 | 1 | 2021 |
| Safety and efficacy study of CRISPR/Cas9 treatment of sickle cell disease in clinically relevant conditions highlights disease-specific response G Frati, M Brusson, G Sartre, B Mlayah, T Felix, A Chalumeau, P Antoniou, ... bioRxiv, 2024.01. 14.575586, 2024 | | 2024 |
| Base editing approaches for the treatment of betahemoglobinopathies A Miccio, P Antoniou, M Cavazzana US Patent App. 17/998,603, 2023 | | 2023 |
| Base editing as a potential therapeutic strategy for motor neuron diseases X Mingaj, S Ciura, E Pasho, P Antoniou, P Martinucci, A Miccio, E Kabashi HUMAN GENE THERAPY 33 (23-24), A146-A147, 2022 | | 2022 |
| Sharpening the adenine and cytosine base editing outcome in hematopoietic stem cells P Antoniou, G Hardouin, M Zoccheddu, P Martinucci, T Felix, ... HUMAN GENE THERAPY 33 (23-24), A17-A17, 2022 | | 2022 |
| Development of a universal prime editing strategy for the treatment of beta-hemoglobinopathies A Chalumeau, P Antoniou, G Hardouin, P Loganathan, M Brusson, ... HUMAN GENE THERAPY 33 (23-24), A68-A69, 2022 | | 2022 |
| Targeted Base Editing Strategies for Beta-Hemoglobinopathies G Hardouin, P Antoniou, P Martinucci, T Felix, M Zoccheddu, ... Blood 140 (Supplement 1), 7778-7779, 2022 | | 2022 |
| Two Is Better Than One: Fetal Hemoglobin Reactivation and Alpha-Globin Downregulation to Correct the β-Hemoglobinopathy Phenotype through Base Editing P Antoniou, M von Joest, L Fontana, G Hardouin, P Martinucci, ... Blood 140 (Supplement 1), 7788-7789, 2022 | | 2022 |
| Base Editing of a gamma-Globin cis-Regulatory Elementin Human Hematopoietic Stem Cells for Reactivation of Therapeutic Fetal Hemoglobin P Antoniou, G Hardouin, P Martinucci, G Frati, T Felix, A Chalumeau, ... MOLECULAR THERAPY 30 (4), 7-8, 2022 | | 2022 |
| Adenine Base Editor-Mediated Correction of Three Prevalent and Severe beta-Thalassemia Mutations G Hardouin, P Antoniou, P Martinucci, S Manceau, L Joseph, ... MOLECULAR THERAPY 30 (4), 35-35, 2022 | | 2022 |
| Approches d'édition de base pour le traitement des ß-hémoglobinopathies P Antoniou | | 2021 |
| P. 0208 Base editing therapeutic strategies for motor neuron diseases X Mingaj, S Ciura, E Kabashi, P Antoniou, P Martinucci, A Miccio European Neuropsychopharmacology 53, S152, 2021 | | 2021 |
| Base Editing Approaches for the Treatment of beta-hemoglobinopathies through Disruption of the Erythroid-Specific BCL11A Enhancer to Reactivate Fetal Hb P Antoniou, G Hardouin, P Martinucci, M Brusson, G Frati, JP Concordet, ... MOLECULAR THERAPY 29 (4), 108-108, 2021 | | 2021 |
